scorecardresearch
Add as a preferred source on Google
Tuesday, June 23, 2026
TopicIndian pharmaceutical

Topic: Indian pharmaceutical

India should look beyond generics if it wants bigger share of global pharma pie, says NITI Aayog

NITI Aayog's Trade Watch Quarterly report says India remains competitive in generics but lags in biologics, vaccines and advanced therapies, limiting its share of $1.3 tn global market.

How Indian firm Lupin became the world-leading TB medicine maker

Manish Sabharwal and Sundeep Khanna's 'Made in India' is the untold story of Desh Bandhu Gupta, Lupin, and how India became the pharmacy to the world.

Chhindwara’s Coldrif deaths show India’s dangerous irony—pharmacy of the world, failing at home

India’s pharmaceutical sector is valued at $50 billion. It has built its reputation on affordability and accessibility. The deaths in Chhindwara tell a different story.

Trump’s 100% pharma tariffs call for Indian firms to reimagine drug exports. Act quickly

If the US is attempting to force localisation, India should respond aggressively with a proactive agenda. Here’s how.

On Camera

Norway’s Viking Row celebrations in World Cup show why football is the ultimate team sport

Norway's ‘Viking Row’ is charming and aggressive. It says that top players like Erling Haaland and Martin Odegaard are hardened warriors who have set sail to conquer other nations.

Rice, maize, or sugarcane? India’s ethanol push triggers debate over agricultural concerns, subsidies

As grain-based ethanol leads the government's biofuel programme, questions are being raised over water use, foodgrain diversion and hidden subsidies.

Engine core by 2030, test flight by 2034, production by 2036: Rolls-Royce makes final pitch to power AMCA

In interview to ThePrint, Rolls-Royce top official Sashi Mukundan took a dig at rival Safran, saying there are just 3 genuine engine manufacturers, with two in US, the 3rd being them.

Why many parties break up when out of power and some don’t

Ideology keeps parties together, or the glue of power. Without either, you face the ongoing defections at an industrial scale.